Therapeutic Sequencing in ALK(+) NSCLC

Anaplastic lymphoma kinase-rearranged non-small-cell lung cancer (ALK(+) NSCLC) is a model disease for the use of targeted pharmaceuticals in thoracic oncology. Due to higher systemic and intracranial efficacy, the second-generation ALK tyrosine kinase inhibitors (TKI) alectinib and brigatinib have...

Descripción completa

Detalles Bibliográficos
Autores principales: Elsayed, Mei, Christopoulos, Petros
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7912146/
https://www.ncbi.nlm.nih.gov/pubmed/33494549
http://dx.doi.org/10.3390/ph14020080

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7912146/
https://www.ncbi.nlm.nih.gov/pubmed/33494549
http://dx.doi.org/10.3390/ph14020080

Ejemplares similares